Expert bioanalysis solutions to progress your clinical research pipelines.
Optimised bioanalytical solutions for pipeline development
Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.
With over two decades of experience, our bioanalytical lab strives to be at the forefront of scientific innovation, housing the tools and expertise required for successful compound development and market release. Our services seamlessly integrate into your discovery, preclinical, and clinical phases, delivering accurate, reliable, and streamlined bioanalytical solutions for even the most complex programs.
Assessing the immunogenicity of therapeutic drugs is particularly important when considering the significance of anti-drug antibodies (ADA) in clinical studies. Our customisable assay panels are developed through rigorous method development and validation to ensure regulatory and sponsor-specific requirements are met, whilst simultaneously providing provide useful, clinically relevant data to facilitate the progression of your therapeutic pipeline.
Our PD assays, renowned for their sensitivity and specificity, are custom-developed and validated by our expert scientists, in collaboration with your team and according to your requirements. Assays are compatible with sample material from an extensive array of matrices and therefore are suitable for large-scale, high-throughput clinical studies.
Synexa’s comprehensive Pharmacokinetic (PK)/Toxicokinetic (TK) analytical services meticulously assess absorption, distribution, metabolism, excretion and kinetics of toxic substances. Our expertise ensures that customers receive crucial insights, optimising drug safety and efficacy for successful therapeutic development.
Synexa’s specialised bioanalytical labs, deep regulatory expertise and technical proficiencies make us the ideal partner for biosimilar therapeutic development. We tailor our services to each project, encompassing bioequivalence studies, anti-drug antibody (ADA) assessments and more. With a history of successful collaborations, we work closely with customers to navigate the complexities of biosimilar development while meeting stringent timelines and regulatory standards.
Robust and Proven Platforms
CytoFLEX (13 colours)
BD FACSCanto II (8 colours)
BD FACSymphony A3 (28 colours)
Revvity Wizard² Gamma Counter